STOCK TITAN
  1. Home
  2. News
  3. AMGN

AMGEN Inc. - AMGN STOCK NEWS

Welcome to our dedicated news page for AMGEN (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on AMGEN.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AMGEN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AMGEN's position in the market.

News
Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Generate:Biomedicines (GB) Announces Clinical Pipeline Advancements and AI Platform Progress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
AI
-
News
AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Rhea-AI Summary
Amgen (AMGN) to Present at 2024 J.P. Morgan Healthcare Conference with Chairman and CEO Robert A. Bradway. Webcast to be Available for Replay for 90 Days
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
conferences
-
News
AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)
Rhea-AI Summary
Amgen (AMGN) receives a Complete Response Letter from the FDA for LUMAKRAS, confirming the dosing at 960 mg once-daily for patients with KRAS G12C-mutated NSCLC under accelerated approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
News
AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION
Rhea-AI Summary
Amgen (NASDAQ:AMGN) announced two changes to its senior leadership team, appointing James Bradner, M.D., as executive vice president of Research and Development, and chief scientific officer, and naming David M. Reese, M.D., as executive vice president and chief technology officer. These changes underscore the company's commitment to ongoing scientific and technological innovation, reflecting the rapid convergence of 'biotech' and 'tech' to unlock the next frontier of innovation in biotechnology. Bradner will be responsible for advancing Amgen's pipeline, including potential first-in-class medicines in all stages of development, across Amgen's four therapeutic areas of focus. Reese, on the other hand, will be responsible for accelerating the use of technology and AI across all facets of the organization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
News
AMGEN TO SPONSOR THE IRISH OPEN
Rhea-AI Summary
Amgen (NASDAQ:AMGN) continues its sponsorship of the Irish Open following the acquisition of Horizon Therapeutics plc, with the 2024 Amgen Irish Open taking place at the Royal County Down Golf Club in Northern Ireland from Sept. 11-15, 2024. The company also becomes a partner to the KPMG Women's Irish Open. Irish professional golfers Shane Lowry, Pádraig Harrington, Séamus Power, and Brendan Lawlor will now become Amgen golf ambassadors. Amgen's chairman and CEO, Robert A. Bradway, expressed the company's commitment to the Irish community, recognizing the tournament's significant contribution to the Irish economy and national pride. Amgen has a 25-year history in Ireland, employs approximately 1,250 people, and supports various Irish patient organizations and education programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
News
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
Rhea-AI Summary
Amgen (AMGN) receives Priority Review from the FDA for tarlatamab, a potential first-in-class BiTE therapy for advanced small cell lung cancer (SCLC). The Prescription Drug User Fee Action (PDUFA) date is June 12, 2024. The BLA is based on Phase 2 results from the DeLLphi-301 clinical trial, demonstrating antitumor activity and encouraging survival outcomes. Tarlatamab is also being investigated in multiple other studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
News
AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE
Rhea-AI Summary
Amgen (NASDAQ:AMGN) declares a $2.25 per share dividend for Q1 2024, marking the 12th consecutive year of dividend increase. The dividend reflects the company's commitment to innovation and balance sheet improvement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
dividends
-
News
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
Rhea-AI Summary
Amgen (AMGN) presents new data at the 65th ASH Annual Meeting, showcasing the potential of BLINCYTO, KYPROLIS, and biosimilar eculizumab as treatment options for blood cancer patients. The company continues to advance its innovative hematology medicines, emphasizing the expanding potential of its BiTE molecule, BLINCYTO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
News
AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
Rhea-AI Summary
Amgen (AMGN) to Present at Evercore ISI HealthCONx Conference on November 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
1 in 25 carries a genotype that is associated with a shortened lifespan
Rhea-AI Summary
AMGN: deCODE Genetics Study Reveals 1 in 25 Carries Genotype Associated with Shortened Lifespan
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
Stock AMGN logo
AMGEN Inc.

Nasdaq:AMGN

AMGN Rankings

#76 Ranked by Market Cap
#2185 Ranked by Stock Gains
#1025 Ranked by Dividends

AMGN Stock Data

142.36B
534.35M
0.25%
80.73%
1.95%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Thousand Oaks

About AMGN

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.